Navigation Links
Metabolomx test detects lung cancer from breath
Date:12/15/2011

Mountain View, CA December 15, 2011 Metabolomx, a diagnostic company focused on the detection of the metabolomics signature of cancer from exhaled breath, today announces publication of results from the first clinical study demonstrating a breath test that can both detect lung cancer and differentiate between types of lung cancer in humans. This seminal study, conducted at the Cleveland Clinic and led by Dr. Peter Mazzone, used Metabolomx' first-generation colorimetric sensor array, and reported accuracy exceeding 80% in lung cancer detection, comparable to computerized tomography (CT) scan. Further, the study found that Metabolomx' first-generation colorimetric sensor array could identify the subtype of lung cancer (small cell versus adenocarcinoma versus squamous cell) with accuracy approaching 90%.

The availability of a low-cost, non-invasive metabolomic breath signature for lung cancer is particularly timely given the recently announced results of the National Cancer Institute's National Lung Screening Trial (NLST) calling for wider CT screening of high-risk citizens. The breath signature, which reports active tumor metabolism, is thought to provide complementary information to CT, potentially helping clinicians distinguish benign from malignant lung nodules.

The sensor detects the unique pattern of volatile organic compounds (the "metabolic biosignature") present in exhaled breath. The article, "Exhaled Breath Analysis with a Colorimetric Sensor Array for the Identification and Characterization of Lung Cancer," is appearing in the current, online issue of the Journal of Thoracic Oncology (JTO), the official Journal of the International Association for the Study of Lung Cancer.

James R. Jett, MD, Pulmonary Medicine and Medical Oncology, National Jewish Health and Editor-in-Chief of the Journal of Thoracic Oncology, stated, "The JTO is dedicated to publishing the best in clinical research that may one day make a real difference in the care of patients. The currently reported results, should they be confirmed in additional clinical testing, provide a provocative challenge for us to look more closely at 'biosignatures,' as described in the journal article, that may be complementary to detection modalities such as CT scan. The advent of the NLST results demonstrating the value of CT heightens the need for non-invasive, low-cost companion diagnostics, and a metabolomic breath test, if born out in continuing studies, is a candidate to play that role in early lung cancer detection."

"The Cleveland Clinic results just published by the Journal of Thoracic Oncology, the reference journal for lung cancer, demonstrate the broad potential for use of breath analysis in the early detection of lung cancer," commented Paul Rhodes, PhD, Founder and CEO of Metabolomx. "These results show that the first generation of our breath test technology compares well with CT scans. Detection of the metabolomic signature of lung cancer in exhaled breath is non-invasive, rapid, and inexpensive, and will become a valuable adjunct to help assess an indeterminate CT, and may come to have a central role in early detection and differentiation of lung cancer, while lowering costs to the healthcare system."

The article was authored by Peter J. Mazzone, MD, MPH, Cleveland Clinic; Xiao-Feng Wang, PhD, Cleveland Clinic; Yaomin Xu, PhD, Cleveland Clinic; Tarek Mekhail, MD, MSc, Florida Hospital; Mary C. Beukemann, Cleveland Clinic; Jie Na, MS, Cleveland Clinic; Jonathan W. Kemling, PhD, University of Illinois, Chicago; Kenneth S. Suslick, PhD, University of Illinois, Chicago; and Madhu Sasidhar, MD, Cleveland Clinic. Initial results from this study were presented at the American College of Chest Physicians conference in November 2010.

Dr. Mazzone commented, "Our research shows that breath testing may help identify patients with lung cancer, as well as provide us with information that can help with treatment decisions, such as the type of lung cancer, its stage, and prognosis. The accuracy of these non-invasive tests can be further augmented when combined with existing clinical predictors, such as health status and age."

Metabolomx has begun trials of its next-generation sensor array system in an ongoing lung cancer study at the Cleveland Clinic. The Company expects their current generation system to be over 100 times more sensitive at detecting breath chemicals, which are often present in very low concentrations, than the system used in the published study.

About the Study

The study, conducted at the Cleveland Clinic and led by Dr. Peter Mazzone, was designed to develop an exhaled breath biosignature of lung cancer using Metabolomx' colorimetric sensor array and to determine the accuracy of breath biosignatures of lung cancer characteristics with and without the inclusion of clinical risk factors. Breath samples were drawn from 229 individuals, 92 with biopsy-proven, untreated lung cancer and 137 either at a risk for developing lung cancer or with indeterminate lung nodules. Logistic prediction models were developed and statistically validated based on the color changes of the sensor. Age, sex, smoking history, and chronic obstructive pulmonary disease were incorporated in the prediction models.

Key Study Results

  • Approximately 81% accuracy for the detection of lung cancer without regard for subtype
  • Approximately 83%, 85%, and 89% accuracy in discriminating patients with adenocarcinoma, squamous cell, and small cell lung cancer versus controls, demonstrating that the breath test can differentiate lung cancer subtype - the first diagnostic announced to do so.
  • An ability to differentiate Stage I/II from Stage III/IV (approximately 79% accuracy) indicating the ability to identify lung cancer at the earliest stages.


'/>"/>

Contact: Justin Jackson
jjackson@burnsmc.com
212-213-0006
Burns McClellan
Source:Eurekalert

Related medicine news :

1. Biomarker detects graft-versus-host-disease in cancer patients after bone marrow transplant
2. Study: Inexpensive method detects ALK rearrangement in lung cancer patients
3. Simple Saliva Test Detects Your Real Age
4. Brain imaging study of preschoolers with ADHD detects brain differences linked to symptoms
5. Hi-Tech Scan Detects Soldiers Head Injuries
6. Amygdala detects spontaneity in human behavior
7. Self-powered, blood-activated sensor detects pancreatitis quickly and cheaply
8. Protein test detects early-stage, asbestos-related pulmonary cancer
9. New test detects early-stage, asbestos-related pulmonary cancer
10. In pilot study, screening detects potentially serious heart conditions in healthy children
11. Simple blood test detects early emphysema in smokers before symptoms appear
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... ... Houma, LA, celebrates the beginning of a new charity campaign. As part of ... Appointed Special Advocates (CASA). In the belief that children deserve a voice, and ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... If you ... much to handle, you are not alone. According to the Center for Disease Control ... disease, stroke, type 2 diabetes and certain types of cancer, some of the leading ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... program serving the greater Venice, FL area, has initiated a fundraiser for a ... car accident just four days after Christmas. To support this beautiful child who ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic ... of women and men with eating disorders report a history of trauma, research ... development of an eating disorder. , At the 2016 iaedp Symposium, the ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Association of ... AHCC and the Home Health and Hospice ICD-10 Transition Workgroup are working closely ... coding guidance and clarifications, to address concerns over the use of 'A' as ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)...  Avista Pharma Solutions ("Avista Pharma") announced today that ... Officer (CFO). Mr. Setzer is a finance and operations ... roles within growing technology and life science companies. Prior ... Director of Finance at INC Research, a publicly traded ... . Previously, Mr. Setzer served as CFO of Expression ...
(Date:2/8/2016)... 8, 2016 Velano Vascular, a medical technology ... patients and their practitioners, announced today that the company ... will use the proceeds from this financing, an extension ... January 2015, to support the development and commercialization of ... populations. Philadelphia , and ...
(Date:2/8/2016)... Fla. , Feb. 8, 2016 Vestagen ... marketing high performance apparel for healthcare and other demanding ... Chief Executive Officer. He replaces Dale Pfost ... remains Chairman. Mr. Bold is also joining Vestagen,s Board ... a new class of active barrier technologies that combines ...
Breaking Medicine Technology: